- Home
- TCRT vs XBIO Comparison
TCRT vs XBIO Comparison
Compare TCRT & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- XBIO
- Stock Information
- Founded
- TCRT 1998
- XBIO N/A
- Country
- TCRT United States
- XBIO United States
- Employees
- TCRT N/A
- XBIO N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- XBIO Health Care
- Exchange
- TCRT Nasdaq
- XBIO Nasdaq
- Market Cap
- TCRT 4.8M
- XBIO 4.4M
- IPO Year
- TCRT N/A
- XBIO N/A
- Fundamental
- Price
- TCRT $2.40
- XBIO $3.27
- Analyst Decision
- TCRT
- XBIO Hold
- Analyst Count
- TCRT 0
- XBIO 1
- Target Price
- TCRT N/A
- XBIO N/A
- AVG Volume (30 Days)
- TCRT 340.3K
- XBIO 15.4K
- Earning Date
- TCRT 11-13-2025
- XBIO 11-11-2025
- Dividend Yield
- TCRT N/A
- XBIO N/A
- EPS Growth
- TCRT N/A
- XBIO N/A
- EPS
- TCRT N/A
- XBIO N/A
- Revenue
- TCRT $6,000.00
- XBIO $2,446,221.00
- Revenue This Year
- TCRT $5,680,500.00
- XBIO $1.99
- Revenue Next Year
- TCRT N/A
- XBIO $20.00
- P/E Ratio
- TCRT N/A
- XBIO N/A
- Revenue Growth
- TCRT N/A
- XBIO N/A
- 52 Week Low
- TCRT $1.31
- XBIO $2.20
- 52 Week High
- TCRT $6.20
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- TCRT 51.69
- XBIO 54.84
- Support Level
- TCRT $2.20
- XBIO $2.97
- Resistance Level
- TCRT $2.40
- XBIO $3.70
- Average True Range (ATR)
- TCRT 0.20
- XBIO 0.23
- MACD
- TCRT 0.07
- XBIO 0.05
- Stochastic Oscillator
- TCRT 91.71
- XBIO 52.75
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.